It is my hope that the cancer field continues to grow the novel therapy for not only patients with lung cancer, but well beyond. It is critical that the public be aware of how research and clinical trials are catalysts to better the outcomes of patients with cancer.
Brain metastases are a pattern of spread we are seeing more for many tumor types as patients are living longer with metastatic cancer and we more readily use an array of brain imaging technologies when needed.
Although COVID-19 has shaken our lives in so many ways, it’s important to keep our health one of our top priorities while also staying safe. We must find widely acceptable ways to screen for cancer in this new era so that we don’t turn the clock back on the gains we have made in the past few decades.
Mantle Cell Lymphoma (MCL), as described in this issue of CURE®, has an interesting and inspiring story. It was one of the first cancers known to have a genetic abnormality-chromosomal translocation t(11;14).
In the medical community, we know that, at a population level, active surveillance is better for certain men with prostate cancer, so we believe the benefit weighs in their favor. We would like to offer men more certainty that surveillance can work for them and hope that, in the next few years, research will bring that to pass.
Although there is much to learn about the intricacies of how the immune system interacts with cancer, advances are occurring rapidly as immunotherapy for cancer has exploded with myriad ongoing clinical trials and newer drugs coming on line constantly.